Nanovesicles derived from bacteria of genus rhodococcus, and use thereof

A technology of Rhodococcus and vesicles, which is applied in the direction of bacteria-derived medical raw materials, skin care preparations, microbial measurement/testing, etc., and can solve the problems of unreported Rhodococcus bacteria secreting vesicles, unreported diagnostic and therapeutic applications Case and other issues

Pending Publication Date: 2021-08-20
MD HEALTHCARE INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there has been no report on the extracellular secretion of vesicles by Rhodococcus bacteria, especially in the diagnosis and treatment of intractable diseases such as cancer or cardiovascular and cerebrovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanovesicles derived from bacteria of genus rhodococcus, and use thereof
  • Nanovesicles derived from bacteria of genus rhodococcus, and use thereof
  • Nanovesicles derived from bacteria of genus rhodococcus, and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 17

[0103] Hereinafter, preferred embodiments to facilitate understanding of the present invention will be presented. However, the following examples are provided only for easier understanding of the present invention, and the content of the present invention is not limited by the following examples.

Embodiment 1

[0105] Example 1. Analysis of In vivo Absorption, Distribution and Excretion Patterns of Gut Bacteria and Bacteria-Derived Vesicles

[0106] To assess whether bacteria and vesicles derived from bacteria are absorbed systemically through mucus, the following experiments were performed. First, a dose of 50 μg of each of fluorescently labeled enterobacteria and vesicles derived from enterobacteria was administered to the stomach of mice, and the Fluorescence was then measured. As a result of observing the whole image of the mouse, as Figure 1A As shown, the bacteria were not absorbed systemically, but vesicles derived from the bacteria were absorbed systemically at 5 minutes after administration, and strong fluorescence was observed in the bladder 3 hours after administration, making it possible to see that the vesicles were excreted into the urine road. Furthermore, it can be seen that the vesicles are present in vivo until 12 hours after administration (see Figure 1A ). ...

Embodiment 2

[0108] Example 2. Metagenomic Analysis of Bacterial-Derived Vesicles in Clinical Samples

[0109] After first putting blood or urine into a 10 ml tube and sedimenting the suspension by centrifugation (3,500 xg, 10 min, 4°C), only the supernatant was transferred to a new 10 ml tube. After removing bacteria and impurities using a 0.22-μm filter, transfer them to a Centriprep tube (centrifugal filter 50kD) and centrifuge at 1,500×g and 4°C for 15 minutes, discard the material smaller than 50kD, and the residue Concentrate to 10ml. After bacteria and impurities were removed again using a 0.22-μm filter, supernatant was discarded and aggregated pellets were dissolved by performing ultracentrifugation at 150,000×g and 4°C for 3 hours using a 90Ti type rotor in normal saline (PBS).

[0110] 100 μl of vesicles isolated by the method described above were boiled at 100 °C to extract internal DNA from lipids, and then cooled on ice for 5 min. Then, in order to remove residual suspen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The resent invention relates to nanovesicles derived from bacteria of genus Rhodococcus, and a use thereof. The present inventors experimentally ascertained that vesicles in clinical samples of patients with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and dementia are significantly reduced compared to those of normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles separated from the strain are administered, and vesicles derived from bacteria of the genus Rhodococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and thus vesicles derived from bacteria of the genus Rhodococcus, according to the present invention, are expected to be effectively usable for the purpose of developing a method for diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and / or dementia, and a composition for preventing or treating malignant disease, diabetes, stroke, cardiovascular disease, inflammatory lung disease, and / or cranial nerve diseases.

Description

technical field [0001] The present invention relates to nanovesicles derived from bacteria of the genus Rhodococcus and uses thereof, and more particularly, to the use of nanovesicles derived from bacteria of the genus Rhodococcus to diagnose malignant diseases (such as lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, etc.), diabetes, stroke, cardiovascular disease (such as myocardial infarction, etc.), inflammatory lung disease (such as asthma, chronic obstructive pulmonary disease (COPD), etc.) or dementia, and a A composition for preventing, alleviating or treating malignant diseases, diabetes, stroke, cardiovascular diseases, inflammatory lung diseases or cranial nerve diseases, comprising the vesicles. [0002] This application claims the benefit of Korean Patent Application No. 10-2019-0002609 filed on January 9, 2019 and Korean Patent Application No. 10-2020-0002274 filed on January 7, 2020 and the descriptions in these applicat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883C12Q1/689C12Q1/6886C12Q1/6851A23L33/135A61K9/00A61K35/74A61P35/00A61P3/10A61P9/10A61P9/00A61P11/00A61P25/00A61Q19/00
CPCA23L33/135A61K35/74C12Q1/6883C12Q1/6886C12Q1/689C12Q2600/158A61P25/00A61P29/00A61P11/06Y02A50/30C12Q1/6851A61K9/0073A23V2002/00
Inventor 金润根
Owner MD HEALTHCARE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap